白蛋白结合型紫杉醇联合替吉奥一线治疗晚期胃癌的效果

Effect of Albumin-bound Paclitaxel Combined with Tigio in the First-line Treatment of Advanced Gastric Cancer

目的探讨白蛋白结合型紫杉醇联合替吉奥一线治疗晚期胃癌的效果。方法回顾性选取2022年1月—2023年6月赤峰市医院收治的100例晚期胃癌一线治疗患者的临床资料,按治疗方案不同分为观察组(50例,白蛋白结合型紫杉醇联合替吉奥治疗)与对照组(50例,奥沙利铂联合替吉奥治疗)。对比两组临床疗效、不良反应发生率、血清肿瘤标志物。结果观察组治疗有效率为64.00%(32/50)、疾病控制率88.00%(44/50)均较对照组的42.00%(21/50)、70.00%(35/50)更高,差异有统计学意义(χ^(2)=4.858、4.883,P均<0.05)。观察组不良反应的总发生率为36.00%(18/50)低于对照组的40.00%(20/50),差异无统计学意义(χ^(2)=0.170,P>0.05)。治疗4周期后,观察组的血清肿瘤标志物均低于对照组,差异有统计学意义(P均<0.05)。结论晚期胃癌一线治疗联用白蛋白结合型紫杉醇、替吉奥,可提高治疗效果,保障治疗安全,降低血清肿瘤标志物水平,值得临床借鉴。

Objective To investigate the effect of albumin-bound paclitaxel combined with tigio in the first-line treat⁃ment of advanced gastric cancer.Methods The clinical data of 100 patients with advanced gastric cancer treated in Chifeng Hospital from January 2022 to June 2023 were retrospectively selected.According to different treatment regi⁃mens,they were divided into observation group(50 cases,albumin-bound paclitaxel combined with tigio treatment)and control group(50 cases,oxaliplatin combined with tigio treatment).The clinical efficacy,incidence of adverse re⁃actions and serum tumor markers were compared between the two groups.Results The effective rate of treatment in the observation group was 64.00%(32/50),and the disease control rate was 88.00%(44/50),which were higher than 42.00%(21/50)and 70.00%(35/50)in the control group.The difference was statistically significant(χ^(2)=4.858,4.883,both P<0.05).The total incidence of adverse reactions in the observation group was 36.00%(18/50)lower than 40.00%(20/50)in the control group,and the difference was not statistically significant(χ^(2)=0.170,P>0.05).After 4 cycles of treatment,the serum tumor markers in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion The first-line treatment of advanced gastric can⁃cer combined with albumin-bound paclitaxel and tigio can improve the therapeutic effect,ensure the safety of treat⁃ment,and reduce the level of serum tumor markers,which is worthy of clinical reference.